Resalis Therapeutics develops RNA-based therapies targeting the root causes of complex metabolic disorders. The company leverages expertise in non-coding RNA and lipid metabolism to advance its lead candidate, RES-010, for sustained weight loss and improved metabolic health. This program is currently being evaluated in clinical trials for indications including obesity and fatty liver disease.
Funding
$28.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metabolic diseases like obesity and fatty liver disease present significant health challenges, often requiring multifaceted interventions to achieve sustained weight loss and improved metabolic health. Current treatments may not address the underlying molecular mechanisms driving these conditions.
Solution
Resalis Therapeutics is developing RES-010, a non-coding RNA drug candidate designed to treat metabolic diseases by targeting specific micro-RNAs. This therapeutic approach aims to modify the disease course, promoting sustained weight loss and improving overall metabolic health. RES-010 leverages the company's expertise in non-coding RNA and lipid metabolism to offer a potentially more effective and disease-modifying therapy. The drug is currently advancing through clinical trials, building upon promising preclinical data.
Target Audience
The primary target audience includes individuals suffering from metabolic diseases such as obesity and fatty liver disease, as well as healthcare providers specializing in metabolic disorders.
Features
- RES-010: A non-coding RNA drug candidate targeting specific micro-RNAs involved in metabolic regulation.
- Designed to promote sustained weight loss and improve metabolic health markers.
- Addresses the underlying molecular mechanisms of metabolic diseases.
- Currently in clinical trials for obesity and fatty liver disease.